A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Withdrawn before enrolling · Not applicable
Conditions studied: Proteinuric Renal Disease
In brief
Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early in CKD, and is undertreated. Vitamin D may have important effects on factors that drive proteinuria and renal disease progression in patients with proteinuric renal diseases. Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.
Key facts
- Study ID
- NCT00469625
- Run by
- Winthrop University Hospital
- People needed
- 0
- Starts
- 2006-07-01
- Expected to finish
- 2008-01-01
- Last updated by the study team
- 2015-12-28
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Stable chronic kidney disease
- Urine protein : Creatinine ratio > 0.4
- Chronic kidney disease stage 2-4 with eGFR 15-90 ml/min
- PTH (intact) >20 pg/ml and <250 pg/ml
- Age 18-85
- If on ACEI/ARB, then dose optimized (BP, K)
You may not qualify if…
- Failure to provide informed consent
- Glomerunephritis requiring active treatment with immunosuppresive therapy
- Serum phosphorus > 5.2
- Serum calcium (adjusted for albumin)> 10.0
- Active malignancy
- Likelihood of requiring renal replacement therapy within 1 year
- Uncontrolled hypertension
Where it is running
- Winthrop Univ. Hospital — Mineola, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.